bevacizumab + curcumin

A combination therapy consisting of bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF), and curcumin, a polyphenolic compound derived from turmeric. This combination has been studied for its potential synergistic effects in cancer treatment, particularly colorectal cancer. Bevacizumab works by inhibiting angiogenesis (formation of new blood vessels) that supply tumors, while curcumin has demonstrated anti-inflammatory, antioxidant, and potential anti-cancer properties. Studies suggest this combination may enhance anti-tumor efficacy while potentially reducing side effects compared to standard chemotherapy regimens.